Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

363

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients With Non-Small Cell Lung Cancer

Interventions

DRUG: OSE2101
DRUG: Docetaxel
DEVICE: NGS HLAA2 assay

Sponsor

OSE Immunotherapeutics

Collaborators

[object Object]
[object Object]